Trial Profile
The renoprotective effect and safety of a DPP-4 inhibitor, Sitagliptin, in type 2 diabetic patients with a renal dysfunction when changed from other DPP-4 inhibitors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Jul 2018
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary)
- Indications Renal impairment
- Focus Therapeutic Use
- Acronyms REAL
- 02 Jul 2018 Status changed from recruiting to completed.
- 06 Jan 2015 New trial record